Androgenic Alopecia
Conditions
Keywords
autologous stromal vascular fraction, platelet rich plasma, male androgenic alopecia
Brief summary
Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia
Detailed description
40 Patients with androgenic alopecia will be randomly divided into 2 groups Group A (20): will receive 2 session of stromal vascular fraction directly after fat harvesting and processing and stromal vascular fraction extraction with 1 month interval . Group B(20): will be injected with 2 session of Platelet rich plasma 3weeks interval at site of fat harvesting and will be followed 1 month later with fat aspiration from site where Platelet rich plasma was previously injected and this fat will undergo fat processing and stromal vascular fraction extraction followed by 2 session of stromal vascular fraction injection at scalp 1month interval . Patients at both groups will receive topical and systemic antibiotics after stromal vascular fraction injection .
Interventions
PROCEDUREautologous stromal vascular fraction
autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male patients with androgenic alopecia
Exclusion criteria
* Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania. Any other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area. Any systemic disease as autoimmune disorders , cardiac hepatic and renal patients. patients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hair density | at baseline and at 6 month after treatment | Trichoscopy |
| hair shaft thickness | at baseline and at 6 month after treatment | TrichoScan |
Contacts
Primary Contactdina A mahmoud, assistant lecturer
Backup Contactreham E Elsharkawy, Professor
Outcome results
None listed